Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial
Research output: Contribution to journal › Article › peer-review
14Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial'. Together they form a unique fingerprint.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science